Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin in patients with multiple sclerosis.

Christian Kabus1, Martin Hecht, Gudrun Japp

  • 1Praxis für Neurologie und Psychiatrie, Leistikowstr. 2, 14050, Berlin, Germany. Christian.Kabus@freenet.de

Journal of Neurology
|February 16, 2006
PubMed
Summary

Multiple sclerosis (MS) spasticity significantly impacts quality of life. Botulinum toxin offers safe spasticity relief in MS when treatment targets are realistic and approaches are multimodal.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same author

The German Parkinson expert meetings.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Editorial: Cognition in Parkinson's disease.

Frontiers in cognition·2026
Same author

Beyond "Advanced": proposing Fluctuation-Dominant Parkinson's disease as a functional alternative to enable timely device-aided therapy.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Neurology and therapy·2026
Same author

Participatory priority setting of research questions for improving hospital care of adults with childhood-onset intellectual disabilities (PRISMA): a study protocol for a mixed-methods study.

BMJ open·2026

Area of Science:

  • Neurology
  • Rehabilitation Medicine

Background:

  • Spasticity is a near-universal complication of multiple sclerosis (MS), severely affecting patient quality of life and daily functioning.
  • Understanding the multifaceted nature of MS, which differs from monophasic disorders, is crucial for effective spasticity management.

Framework:

  • A multimodal treatment strategy for MS spasticity is recommended.
  • Defining realistic therapeutic targets is essential for successful intervention.

Implementation:

  • Botulinum toxin injections provide an efficient and safe method for alleviating MS-related spasticity.
  • Treatment success hinges on diligent analysis of potential failure points and individualized patient care.

Implications:

  • Optimized botulinum toxin treatment can significantly improve the quality of life for MS patients experiencing spasticity.

Related Experiment Videos

  • Tailoring spasticity management to the unique characteristics of MS is paramount for achieving therapeutic goals.